Recombinant Human ALK-1 is used in research applications primarily to study and manipulate angiogenesis, vascular biology, and TGF-β superfamily signaling, with particular relevance to cancer, cardiovascular, and regenerative medicine research.

Key scientific reasons to use Recombinant Human ALK-1 include:

• Modeling Angiogenesis and Vascular Development: ALK-1 is a type I receptor in the TGF-β superfamily, predominantly expressed in endothelial cells, where it mediates signaling essential for blood vessel formation and vascular stability. Recombinant ALK-1 enables in vitro and in vivo studies of these processes, including endothelial cell sprouting, tube formation, and vessel maturation.

• Cancer Research and Antiangiogenic Therapy: ALK-1 signaling is implicated in tumor angiogenesis and the immunomodulatory microenvironment of cancers. Recombinant ALK-1 can be used to:

  • Investigate the effects of ALK-1 modulation on tumor growth and metastasis.
  • Screen or validate anti-angiogenic compounds, such as ALK-1 inhibitors or ligand traps, which are being explored as cancer therapeutics.
  • Study the recruitment and differentiation of tumor-associated macrophages and their impact on disease progression.

• Cardiovascular and Regenerative Medicine: ALK-1 signaling, especially via its ligand BMP9, is crucial for cardiovascular development, myocardial repair, and maintenance of vascular integrity. Recombinant ALK-1 is used to:

  • Analyze paracrine/autocrine signaling in cardiac progenitor cells and endothelial cells.
  • Investigate mechanisms underlying myocardial repair and vascular regeneration after injury.

• Mechanistic Studies of TGF-β/BMP Pathways: Recombinant ALK-1 allows for controlled biochemical and cell-based assays to dissect ligand-receptor interactions, downstream SMAD signaling, and cross-talk with other pathways. This is essential for understanding the molecular basis of diseases such as hereditary hemorrhagic telangiectasia, where ALK-1 mutations are causative.

• Tool for Antibody and Drug Screening: Recombinant ALK-1 is used as a target for developing and characterizing therapeutic antibodies or small molecules that modulate its activity, as well as for competitive binding and functional assays.

Summary of applications:

• Functional assays of angiogenesis and vascular biology.
• Cancer biology, especially tumor angiogenesis and immune microenvironment studies.
• Cardiovascular research, including myocardial repair and vascular regeneration.
• Mechanistic studies of TGF-β/BMP signaling.
• Screening and validation of ALK-1-targeted therapeutics.

Using recombinant ALK-1 provides a defined, reproducible system to interrogate these pathways, enabling both basic mechanistic research and translational drug development.

Yes, you can use recombinant human ALK-1 as a standard for quantification or calibration in ELISA assays, provided it is sufficiently pure and its concentration is accurately determined. This is a common practice in quantitative ELISA protocols, where a recombinant protein serves as the reference antigen for generating a standard curve.

Key considerations and best practices:

• Purity and Identity: The recombinant ALK-1 should be highly purified and well-characterized to ensure it represents the analyte detected by your ELISA antibodies.
• Accurate Quantification: The concentration of the recombinant standard must be precisely measured, typically by absorbance at 280 nm, BCA assay, or another validated protein quantification method.
• Standard Curve Preparation: Prepare serial dilutions of the recombinant ALK-1 in the same matrix as your samples (e.g., serum, plasma, buffer) to minimize matrix effects and ensure accurate quantification.
• Validation: Confirm that the recombinant ALK-1 is recognized equivalently by the ELISA antibodies compared to endogenous ALK-1. This can be assessed by spike-and-recovery experiments and parallelism testing.
• Lot-to-Lot Variability: Be aware that different lots of recombinant protein may have slight differences in immunoreactivity or mass determination, so it is best to value-assign the standard concentration based on ELISA measurement rather than relying solely on the vial label.

Protocol summary for ELISA calibration with recombinant ALK-1:

1. Reconstitute or dilute recombinant ALK-1 to a known concentration.
2. Prepare a series of standards covering the expected range of detection (e.g., 0.156–10 ng/mL, as commonly used in ALK-1 ELISA kits).
3. Run the standards in parallel with your samples on the ELISA plate.
4. Generate a standard curve by plotting the measured signal (e.g., absorbance) against the known concentrations.
5. Use the curve to interpolate the concentration of ALK-1 in your samples.

Additional notes:

• Some commercial ELISA kits include a recombinant ALK-1 standard, but you can substitute with your own recombinant preparation if it is validated for the assay.
• Always prepare a fresh standard curve for each assay run to account for day-to-day and plate-to-plate variability.
• If using a recombinant ALK-1 fragment or fusion protein, ensure the epitope recognized by the ELISA antibodies is present and accessible.

In summary: Recombinant human ALK-1 is suitable as a calibration standard for ELISA quantification, provided you follow best practices for protein quantification, validation, and standard curve preparation.

Applications of Recombinant Human ALK-1 in Published Research

Recombinant human ALK-1 has been validated for several important research applications across multiple scientific domains:

Angiogenesis and Vascular Biology Research

ALK-1 recombinant proteins serve as critical tools for studying angiogenic signaling pathways. The extracellular domain of ALK-1 has been immobilized on biosensor chips to investigate ligand binding kinetics using surface plasmon resonance, enabling detailed characterization of how ALK-1 interacts with its ligands BMP9 and TGF-β. This application has been fundamental in understanding the molecular mechanisms underlying endothelial cell sprouting and vascular development.

Therapeutic Target Validation

Recombinant ALK-1 has been extensively used to validate ALK-1 as a therapeutic target in antiangiogenesis therapy. Studies have demonstrated that ALK-1-Fc, a soluble chimeric protein consisting of the extracellular portion of ALK-1 fused to an Fc fragment, effectively reduces tumor burden in preclinical models. In orthotopic breast cancer models, ALK-1-Fc treatment achieved a 70% reduction in tumor burden, while in pancreatic cancer models, it reduced tumor growth and progression through decreased tumor angiogenesis.

Cardiac Progenitor Cell Research

ALK-1 signaling in human cardiac progenitor cells has been validated as a regulator of pro-angiogenic properties. When activated by BMP9, ALK-1 signaling promotes a pro-angiogenic secretome that increases capillary-like tube formation, making recombinant ALK-1 valuable for studying myocardial repair mechanisms in cell-based therapeutic approaches.

Protein Characterization Applications

Recombinant ALK-1 proteins have been validated for standard biochemical applications including SDS-PAGE analysis and ELISA assays. These applications support protein characterization, purity assessment, and quantification in research workflows.

To reconstitute and prepare Recombinant Human ALK-1 protein for cell culture experiments, follow these general best practices, which are consistent with protocols for recombinant proteins and specifically supported by available technical documentation:

• Centrifuge the vial briefly (10–30 seconds in a microcentrifuge) before opening to ensure all lyophilized protein is at the bottom.
• Use sterile, deionized water for initial reconstitution unless the Certificate of Analysis (CoA) or product datasheet specifies a different buffer (such as PBS).
• Add water gently: Do not vortex. Add the recommended volume of sterile water (typically 100–1000 µL, depending on the amount of protein and desired concentration), and gently swirl or invert the vial to dissolve the protein completely.
• Target concentration: Reconstitute to a final concentration of 0.1–1.0 mg/mL for most applications. For example, add 100 µL to 1 mg of protein for a 1 mg/mL solution, or 1 mL for a 0.1 mg/mL solution.
• Optional additives: For improved stability, especially if storing aliquots, you may add carrier proteins (e.g., 0.1% BSA) or glycerol (final 5–50%) after initial reconstitution, if compatible with your downstream application.
• Aliquot and storage: After reconstitution, aliquot the solution to avoid repeated freeze-thaw cycles. Store at 2–8 °C for short-term use (up to 1 month) or at –20 °C to –70 °C for long-term storage.
• Avoid repeated freeze-thaw cycles to maintain protein integrity.

Critical note: Always consult the specific CoA or product datasheet for your ALK-1 protein lot, as formulation (e.g., presence of trehalose, PBS, or other excipients) and recommended reconstitution buffer may vary by manufacturer and expression system.

Summary protocol:

1. Briefly centrifuge the vial.
2. Add sterile deionized water (or specified buffer) to achieve 0.1–1.0 mg/mL.
3. Gently mix to dissolve; do not vortex.
4. If needed, add stabilizers (BSA, glycerol) after dissolution.
5. Aliquot and store appropriately.

These steps will ensure maximum solubility, stability, and bioactivity of recombinant ALK-1 for cell culture experiments.